ArticleCellular oncology (Dordrecht, Netherlands)2026
Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) stands as a predominant contributor to cancer-related mortality, with angiogenesis serving a pivotal role in the advancement of the disease. The upregulation of LINC00323 in NSCLC has been identified; however, its function in facilitating NSCLC progression remains ambiguous. This investigation delves into the implications of LINC00323 on cellular proliferation, angiogenesis, and associated pathways in NSCLC, emphasizing its regulation of CDC5L stability and its presence within exosomes.
methodsThe expression of LINC00323 was scrutinized in NSCLC tissues and cells through RT-qPCR and FISH techniques. The influence of LINC00323 and exosomes derived from NSCLC cells with modified LINC00323 expression on cellular proliferation and angiogenesis was evaluated in A549 and H358 cell lines. Co-culture with HUVECs was employed to assess endothelial functionality. RNA pull-down assays and proteomic analyses identified CDC5L as a downstream target of LINC00323. The activation of MAPK and JAK-STAT pathways was investigated via Western blotting.
resultsThe results indicated that LINC00323 was significantly upregulated in NSCLC tissues, correlating with a poorer prognosis and heightened angiogenesis. Overexpression of LINC00323 facilitated cellular proliferation and angiogenesis, while its knockdown impeded these processes. Moreover, exosomes containing LINC00323 from NSCLC cells stimulated angiogenesis and preserved endothelial barrier integrity in HUVECs. LINC00323 was shown to directly interact with and stabilize CDC5L. Functional complementation experiments demonstrated that the knockdown of CDC5L counteracted the effects of LINC00323 overexpression on cellular proliferation, angiogenesis, and the MAPK/JAK-STAT pathways in vitro. In vivo studies revealed that LINC00323 knockdown in A549 xenografts led to reductions in tumor size, angiogenesis, and the MAPK and JAK-STAT pathways, with CDC5L overexpression mitigating these effects.
conclusionsLINC00323 within exosomes accelerates the progression of NSCLC and activates the MAPK and JAK-STAT pathways by stabilizing CDC5L. These findings underscore LINC00323 as a potential therapeutic target for NSCLC, particularly in its modulation of the angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.